[1]
Wall, M.E.; Wani, M.C.; Cook, C.E. Plant antitumor agents I. The isolation and structure of camptothecin: A novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate. J. Am. Chem. Soc., 1966, 16, 3888-3890.
[2]
Chabner, B.A.; Roberts, T.G. Timeline: Chemotherapy and the war on cancer. Nat. Rev. Cancer, 2005, 5, 65-72.
[3]
Friedl, P.; Wolf, K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat. Rev. Cancer, 2003, 3, 362-374.
[4]
Yadav, D.K.; Khan, F. QSAR; docking and ADMET studies of camptothecin derivatives as inhibitors of DNA topoisomerase-I. J. Chemometrics, 2013, 27, 21-33.
[5]
Vishnuvajjala, B.R.; Garzon-Aburbeh, A. Water soluble prodrugs
of camptothecin. U.S. Patent 4,943,579, July 24, 1990.
[6]
Jin, C.; Zhang, Q.M.; Lu, W. Synthesis and biological evaluation of hypoxia-activated prodrugs of SN-38. Eur. J. Med. Chem., 2017, 132, 135-141.
[7]
Manjeet, D.; Chao, P.Y.; Kutscher, H.L.; Gao, D.Y.; Sinko, P.J. A series of α-amino acid ester prodrugs of camptothecin: In vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity. J. Med. Chem., 2010, 53(3), 1038-1047.
[8]
Hill, T.A.; Stewart, S.G.; Sauer, B.; Gilbert, J.; Ackland, S.P.; Sakoff, J.A.; McCluskey, A. Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity. Bioorg. Med. Chem. Lett., 2007, 17, 3392-3397.
[9]
Essers, M.; Wibbeling, B.; Haufe, G. Synthesis of the first fluorinated cantharidin analogues. Tetrahedron Lett., 2001, 42, 5429-5433.
[10]
Miao, Z.Y.; Zhu, L.J.; Dong, G.Q.; Zhuang, C.L.; Wu, Y.L.; Wang, S.Z.; Guo, Z.Z.; Liu, Y.; Wu, S.C.; Zhu, S.P.; Fang, K.; Yao, J.Z.; Li, J.; Sheng, C.Q.; Zhang, W.N. A new strategy to improve the metabolic stability of lactone: Discovery of (20S; 21S)-21-Fluoro camptothecins as novel: Hydrolytically stable topoisomerase I inhibitors. J. Med. Chem., 2013, 56, 7902-7910.
[11]
Sun, P.; Chen, D.; Deng, H.P.; Wang, N.; Huang, P.; Jin, X.; Zhu, X.Y. “Bottom-up” construction of multi-polyprodrug-arm hyperbranched amphiphiles for cancer therapy. Bioconjug. Chem., 2017, 28(5), 1470-1480.
[12]
Xie, H.Y.; Xu, X.; Chen, J.M.; Li, L.L.; Wang, J.G.; Fang, T.; Zhou, L.; Wang, H.X.; Zhen, S.S. Rational design of multifunctional small-molecule prodrugs for simultaneous suppression of cancer cell growth and metastasis in vitro and in vivo. Chem. Commun., 2016, 32, 5601-5604.
[13]
Cai, Y.B.; Shen, H.S.; Zhan, J.; Lin, M.L.; Dai, L.H.; Ren, C.H.; Shi, Y.; Liu, J.F.; Gao, J.; Yang, Z.M. Supramolecular “Trojan Horse” for nuclear delivery of dual anticancer drugs. J. Am. Chem. Soc., 2017, 139(8), 2876-2879.
[14]
Wang, X.H.; Yang, F.H.; Zhao, C.K.; Gao, L.; Li, C. Sealed tube promoted coupling of camptothecin and norcantharidin acid ester and their preliminary biological activity evaluation in vitro. Med. Chem. Res., 2018, 27, 406-411.
